Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.

Abstract

Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.

• Authors: E H Kraut, J Bendetti, S P Balcerzak, J H Doroshow
• Journal: Investigational new drugs (Invest New Drugs) Vol. 10 Issue 4 Pg. 347-9 (Nov 1992) ISSN: 0167-6997 [Print] United States
• PMID: 1487411 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Thiobarbiturates
• merbarone

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Drug Administration Schedule
• Female
• Humans
• Infusions, Intravenous
• Male
• Middle Aged
• Sarcoma (drug therapy)
• Soft Tissue Neoplasms (drug therapy)
• Thiobarbiturates (administration & dosage, adverse effects, therapeutic use)